



7. -- 2006

PTO/SB/21 (09-04)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

<b>Application Number</b>	10/553,459	
	<b>Filing Date</b>	October 17, 2005
	<b>First Named Inventor</b>	Paul HALLENBECK
	<b>Art Unit</b>	
	<b>Examiner Name</b>	
<b>Attorney Docket Number</b>	3802-165-27 NATL	
<b>Total Number of Pages in This Submission</b>	14 pgs	

## ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Sixty-nine (69) References
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	Return-receipt postcard
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		
<b>Remarks</b> The Commissioner is authorized to charge any deficiencies in fees and credit any overpayment of fees to Deposit Account No. 07-1896. A duplicate page is enclosed.		

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

<b>Firm Name</b>	DLA Piper Rudnick Gray Cary US LLP, 1200 Nineteenth Street, N.W., Washington, DD 20036-2412		
<b>Signature</b>			
<b>Printed name</b>	Linda R. Judge, Telephone: 415-836-2586, Facsimile: 415-836-2501		
<b>Date</b>	February 22, 2006	<b>Reg. No.</b>	42,702

## CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:			
<b>Signature</b>			
<b>Typed or printed name</b>	Kathleen A. Farrell	<b>Date</b>	February 22, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



FEB 27 2006 Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

### Complete if Known

Application Number	10/553,459
Filing Date	October 17, 2005
First Named Inventor	PAUL HALLENBECK
Art Unit	
Examiner Name	
Attorney Docket Number	3802-165-27 NATL

Sheet 1 of 2

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In accordance with the provisions of 37 C.F.R. § 1.56(a) and 37 C.F.R. § 1.97, Applicant(s) hereby make of record the references listed on the accompanying form, SB/08A and/or SB/08b for consideration by the Examiner in connection with the examination of the above-identified patent application.

#### This Information Disclosure Statement:

- (a) accompanies a new patent application submitted herewith.
- (b) ☒ **is filed within three (3) months of the Filing Date or before the mailing date of a First Office Action on the merits; OR**
- (c) is filed after the first Office Action and more than three months after the application's filing date or PCT national stage date of entry filing but, as far as is known to the undersigned prior to the mailing date of either a final rejection or a notice of allowance, and is accompanied by either the fee (\$180) set forth in 37 CFR § 1.17(p) or a certification as specified in 37 CFR § 1.97(e), as checked below **OR**
- (d) is filed after the mailing date of either a final rejection or a notice of allowance, and the issue fee has not been paid, and is accompanied by the requisite petition fee (\$130) set forth in 37 CFR § 1.17(l)(1) and a certification as specified in 37 CFR § 1.97(e), as checked below. This document is to be considered as a petition requesting consideration of the information disclosure statement.

As required under § 1.97(e), Applicants, through the undersigned, hereby state either that [check the appropriate space]:

- (e) Each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of the Information Disclosure Statement; or
- (f) No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

Each item of information listed in the attached FORM PTO/SB/08a and/or SB/08b may be material to the examination of the above-identified application and is, therefore, submitted in compliance with the duty of disclosure defined in 37 CFR 1.56, 1.97 and 1.98. The Examiner is requested to make these items of official record in this application.

Pursuant to notice entitled "Information Disclosure Statements May Be Filed Without Copies Of U.S. Patents and Published Applications in Patent Applications filed after June 30, 2003," *Off. Gaz. Pat. Office* 55 (August 5, 2003), no copies of U.S. Patents and U.S. Published Patent Applications are being supplied with this Information Disclosure Statement.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/553,459
		Filing Date	October 17, 2005
		First Named Inventor	PAUL HALLENBECK
		Art Unit	
		Examiner Name	
Sheet 2	of 2	Attorney Docket Number	3802-107

This Information Disclosure Statement under 37 CFR 1.56, 1.97 and 1.98 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these items constitutes prior art.

If this statement crosses in the mail with an office action, or is otherwise not in the indicated category of 37 C.F.R. 1.97, it is respectfully requested that this statement be treated in the next appropriate category and made of record. To the extent required, please treat this submission as a conditional petition for acceptance of the information disclosure statement.

The Commissioner is authorized to charge any deficiencies and credit any overpayment of fees to our Deposit Account No. 07-1896.

Respectfully submitted,

Date: February 22, 2006

DLA Piper Rudnick Gray Cary US LLP



By: Linda R. Judge

Reg. No. 42,702

Attorneys for Applicant(s)

1200 Nineteenth Street, N.W.

Washington D.C. 20036-2412

Tel. (202) 861-3900

Fax. (202) 223-2085

Customer Number or Bar Code Label

(Insert Customer No. or Attach bar code label here)

**Certificate of Mailing**

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope, addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

2/22/06  
Date

Kathleen A. Farrell  
Kathleen A. Farrell

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/553,459
				Filing Date	October 17, 2005
				First Named Inventor	PAUL HALLENBECK
				Examiner Name	
Sheet	1	of	8	Attorney Docket Number	3802-165-27 NATL

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-5,543,328	08-06-1996	MCCLELLAND, et al.	
	AB	US-5,731,190	03-24-1998	WICKHAM, et al.	
	AC	US-5,747,469	05-05-1998	ROTH, et al.	
	AD	US-5,756,086	05-26-1998	MCCLELLAND, et al.	
	AE	US-5,801,029	09-01-1998	MCCORMICK	
	AF	US-5,846,945	12-08-1998	MCCORMICK	
	AG	US-5,992,315	11-30-1999	LORENZ	
	AH	US-5,962,311	10-05-1999	WICKHAM, et al.	
	AI	US-5,994,128	11-30-1999	FALLAUX, et al.	
	AJ	US-6,033,908	03-27-2000	BOUT, et al.	
	AK	US-6,057,155	05-02-2000	WICKHAM, et al.	
	AL	US-6,127,525	10-03-2000	CRYSTAL, et al.	
	AM	US-6,153,435	11-28-2000	CRYSTAL, et al.	
	AN	US-6,455,314	09-24-2002	WICKHAM, et al.	
	AO	US-6,638,762	10-28-2003	CHANG, et al.	
	AP	US-6,676,935	01-13-2004	HENDERSON, et al.	
	AQ	US-6,692,736	02-17-2004	YU, et al.	

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	AR	WO 00/15820	03-23-2000	YU et al.		
	AS	WO 00/46355	08-10-2000	MORIN et al.		
	AT	WO 01/92299	12-06-2001	JAKUBCZAK et al.		
	AU	WO 02/067861	09-06-2002	ENNIST et al.		
	AV	WO 02/068627	09-06-2002	GORZIGLIA et al.		
	AW	WO 95/19434	07-20-1995	HENDERSON		
	AX	WO 98/07877	02-26-1998	WICKHAM et al.		
	AY	WO 98/13508	04-02-1998	FINE et al.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

SANF11339219.1  
306229-327

[illegible]

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	AZ	WO 98/14593	04-09-1998	CECH et al.		
	BA	WO 98/29555	07-09-1998	BISCHOFF et al.		
	BB	WO 98/35554	08-20-1998	NIELSEN et al.		
	BC	WO 98/39464	09-11-1998	HENDERSON et al.		
	BD	WO 98/39465	09-11-1998	LITTLE et al.		
	BE	WO 98/39466	09-11-1998	YU et al.		
	BF	WO 98/39467	09-11-1998	LAMPARSKI et al.		
	BG	WO 99/06576	02-11-1999	YU et al.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

SANF1\339219.1  
306229-327

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE  STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/553,459
				Filing Date	October 17, 2005
				First Named Inventor	PAUL HALLENBECK
				Art Unit	
				Examiner Name	
Sheet	3	of	8	Attorney Docket Number	3802-165-27 NATL

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	BH	WO 99/25860	05-27-1999	CHANG et al.		
	BI	WO 99/59604	11-25-99	KIRN		
	BJ	WO 99/62942	12-09-1999	AFAR et al.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE  STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/553,459
				Filing Date	October 17, 2005
				First Named Inventor	PAUL HALLENBECK
				Art Unit	
				Examiner Name	
Sheet	4	of	8	Attorney Docket Number	3802-165-27 NATL

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	BK	ALTSCHUL et al., Basic Local Alignment Search Tool, Journal Molecular Biology, (1990), Vol. 215, pp. 403-410, Academic Press Limited.	
	BL	BERKNER et al., Generation of adenovirus by transfection of plasmids, (1983), Nucleic Acid Research, Vol. 11, pp. 6003-6020, Center for Cancer Research and Department of Biology.	
	BM	BETT et al., An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3, Proc. Natl. Acad. Sci. (1994), Vol. 91, pp. 8802-8806, Medical Sciences.	
	BN	BITTNER et al., Expression and Secretion Vectors for Yeast, Methods in Enzymology, (1987), Vol. 153, pp. 516-544, Academic Press, Inc.	
	BO	BLACKWOOD et al., Going the Distance: A Current View of Enhancer Action, Science (1998), Vol. 281, pp. 60-63 Department of Biology and Center for Molecular Genetics.	
	BP	BRIDGE et al., Redundant Control of Adenovirus Late Gene Expression by Early Region 4, Journal of Virology, (1989), Vol. 63, No. 2, pp. 631-638, American Society for Microbiology.	
	BQ	CANNIO et al., A cell-type specific and enhancer-dependent silencer in the regulation of the expression of the human urokinase plasminogen activator gene, Nucleic Acids Research (1991) Vol. 19, No. 9, pp. :2303-2308, Oxford University Press.	
	BR	CHAO et al., Assembly of the Cleavage and Polyadenylation Apparatus Requires about 10 Seconds In Vivo and Is Faster for Strong than for Weak Poly(A) Sites, Molecular and Cellular Biology, (1999), Vol. 19, No. 8, pp. 5588-5600, American Society for Microbiology.	
	BS	DEMOTT et al., Human RAD2 Homolog 1 5' - to 3' - Exo/Endonuclease Can Efficiently Excise a Displaced DNA Fragment Containing a 5'-Terminal Abasic Lesion by Endonuclease Activity, Journal of Biological Chemistry, (1996), Vol. 271, pp. 30068-30076, The American Society for Biochemistry and Molecular Biology, Inc.	
	BT	DONNELLY et al., Analysis of the aphthovirus 2A/2B polypeptide 'cleavage' mechanism indicates not a proteolytic reaction, but a novel translational effect: a putative ribosomal 'skip', Journal of General Virology (2001), Vol. 82, pp. 1013-1025.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, US. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE  STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/553,459
				Filing Date	October 17, 2005
				First Named Inventor	PAUL HALLENBECK
				Art Unit	
				Examiner Name	
Sheet	5	of	8	Attorney Docket Number	3802-165-27 NATL

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	BU	DONNELLY et al., The 'cleavage' activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring '2A-like sequences, Journal of General Virology, (2001), Vol. 82, pp. 1027-1041		
	BV	DUKE et al., Sequence and Structural Elements That Contribute to Efficient Encephalomyocarditis Virus RNA Translation, Journal of Virology (1992), Vol. 66, No. 3, pp. 1602-1609, American Society for Microbiology.		
	BW	FALLAUX et al., New Helper Cells and Matched Early Region 1-Deleted Adenovirus Vectors Prevent Generation of Replication-Competent Adenoviruses, Human Gene Therapy, (1998), Vol. 9, pp. 1909-1917, Mary Ann Liebert, Inc.		
	BX	FURLER et al., Recombinant AAV vectors containing the foot and moth disease virus 2A sequence confer efficient vicistronic gene expression in cultured cells and rat substantia nigra neurons, Gene Therapy, (2001), Vol. 8, pp. 864-873, Nature Publishing Group.		
	BY	GORZIGLIA et al., Elimination of both E1 and E2a from Adenovirus Vectors Further Improves Prospects for In Vivo Human Gene Therapy, Journal of Virology, (1996), Vol. 70, No. 6, pp. 4173-4178, American Society for Microbiology.		
	BZ	GRAHAM et al., Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5, Journal General Virology, (1977) Vol. 36, pp. 59-72, National Institute for Medical Research.		
	CA	GUGGENHEIMER et al., Protein-primed Replication of Plasmids Containing the Terminus of the Adenovirus Genome, Journal Biological Chemistry (1984), Vol. 259, No. 12: pp. 7815-7825, American Society for Microbiology.		
	CB	HARRINGTON AND LIEBER, The Characterization of a mammalian DNA structure-specific endonuclease, EMBO Journal, (1994), Vol. 13, No. 5, pp. 1235-1246, Oxford University Press.		
	CC	HARRINGTON AND LIEBER, DNA Structural Elements Required for FEN-a Binding, Journal Biological Chemistry, (1995), Vol. 270, No. 9, pp. 4503-4508, American Society for Biochemistry and Molecular Biology, Inc.		
	CD	HE et al., A simplified system for generating recombinant adenoviruses, Proc. Natl. Acad. Sci. (1998), Vol. 95, No. 5, pp. 2509-2514, Medical Sciences.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE  STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/553,459
				Filing Date	October 17, 2005
				First Named Inventor	PAUL HALLENBECK
				Art Unit	
				Examiner Name	
Sheet	6	of	8	Attorney Docket Number	3802-165-27 NATL

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CE	HUEZ et al., Two Independent Internal Ribosome Entry Sites Are Involved in Translation Initiation of Vascular Endothelial Growth Factor mRNA, Molecular and Cellular Biology, (1998), Vol. 18, No. 11, pp. 6178-6190, American Society for Microbiology.	
	CF	JACKSON, R.J. et al., Internal initiation of translation in eukaryotes: The picornavirus paradigm and beyond, RNA Society, (1995), Vol.1, No. 10, pp. :985-1000, Cambridge University Press.	
	CG	JACKSON, R.J. et al., The initiation of translation of picornaviral RNAs, Trends in Biochemistry Science (1990), Vol.15, No. 12, pp.477-483, Elsevier Science Publishers Ltd.	
	CH	LI et al., Lagging Strand DNA Synthesis at the Eukaryotic Replication Fork Involves Binding and Stimulation of FEN-1 by Proliferating Cell Nuclear Antigen, Journal of Biological Chemistry (1995), Vol. 270, No. 38, pp. 22109-22112, American Society for Biochemistry and Molecular Biology, Inc.	
	CI	LINDAHL, Excision of Pyrimidine Dimers from Ultraviolet-Irradiated DNA by Exonucleases from Mammalian Cells, Eur. Journal Biochem, (1971), Vol. 18, pp. 407-414.	
	CJ	LOGAN & SHENK, Adenovirus tripartite leader sequence enhances translation of mRNAs late after infection, Proc. Nat'l Acad. USA (1984), Vol. 81, pp. 3655-3659, Biochemistry.	
	CK	MCKINNON et al., Tn5 mutagenesis of the transforming genes of human adenovirus type 5, Gene (1982), Vol. 19, pp. 33-42, Elsevier Biomedical Press.	
	CL	MULLIGAN et al., Expression of a Bacterial Gene in Mammalian Cells, Science (1980), Vol. 209, pp. 1422-1427, AAAS.	
	CM	NEEDLEMAN & WUNSCH, A General Method Applicable to the Search for Similarities in the Amino acid Sequence of Two Proteins, Journal Molecular Biology, (1970), Vol. 48, pp. 443-453.	
	CN	PALMENBERG, Proteolytic Processing Of Picornaviral Polyprotein, Annual Review Microbiology, (1990), Vol. 44, pp. 603-623, Annual Reviews, Inc.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/553,459
				Filing Date	October 17, 2005
				First Named Inventor	PAUL HALLENBECK
				Art Unit	
				Examiner Name	
Sheet	7	of	8	Attorney Docket Number	3802-165-27 NATL

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CO	PARR et al., Tumor-selective transgene expression <i>in vivo</i> mediated by an E2F-responsive adenoviral vector, <i>Nature Medicine</i> 1997, Vol. 3, No. 10, pp. 1145-1149, Annual Reviews Inc.	
	CP	PEARSON & LIPMAN, Improved tools for biological sequence comparison, <i>Proc. Nat'l Acad. Sci. USA</i> , (1988) Vol.85, pp. 2444-2448, Biochemistry.	
	CQ	PRICE AND LINDAHL, Enzymatic Release of 5'-Terminal Deoxyribose Phosphate Residues from Damaged DNA in Human Cells, <i>Biochemistry</i> (1991), Vol. 30, pp. 8631-8637, American Chemical Society.	
	CR	RAO et al., The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins, <i>Proc. Nat'l Acad. Sci. USA</i> , (1992), Vol. 89, pp. 7742-7746, Cell Biology.	
	CS	RICCIO et al., The human urokinase-plasminogen activator gene and its promoter, <i>Nucleic Acids Research</i> , (1985), Vol. 13, No. 8, pp. 2759-2771, IRL Press Limited.	
	CT	SAHA et al., A Phosphatase Associated with Metastasis of Colorectal Cancer, <i>Science</i> (2001), Vol. 294: pp. 1343-1346	
	CW	SIEGAL et al., A 5' to 3' exonuclease functionally interacts with calf DNA polymerase $\epsilon$ , <i>Proc. Natl. Acad. Sci.</i> (1992), Vol. 89, pp. 9377-9381, Biochemistry.	
	CX	SMITH & WATERMAN, Comparison of Biosequences, <i>Advances in Applied Math</i> , (1981), Vol 2: pp. 482-489, Academic Press, Inc.	
	CY	SMITH et al., Transcriptional Regulation of Mammalian Genes <i>in Vivo</i> , <i>Journal Biological Chemistry</i> , (1997), Vol. 272, pp. 27493-27496, National Institute of Health.	
	CZ	SOUTHERN et al., Transformation of Mammalian Cells to Antibiotic Resistance with a Bacterial Gene Under Control of the SV40 Early Region Promoter, <i>Journal Molecular Applied Genetics</i> (1982), Vol. 1, pp. 327-341, Raven Press.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, US. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/553,459
				Filing Date	October 17, 2005
				First Named Inventor	PAUL HALLENBECK
				Art Unit	
				Examiner Name	
Sheet	8	of	8	Attorney Docket Number	3802-165-27 NATL

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	DA	SUGDEN et al., A Vector That Replicates as a Plasmid and Can Be Efficiently Selected in B-Lymphoblasts Transformed by Epstein-Barr Virus, Molecular and Cellular Biology (1985), Vol. 5, No. 2, pp. :410-133, American Society for Microbiology.		
	DB	SWAMINATHAN et al., Regulation of Adenovirus E2 Transcription Unit, Current Topics in Microbiology and Immunology(1995), Vol. 199, Part 3, pp. 177-194.		
	DC	TOLLEFSON et al., The 11,600-M <sub>w</sub> Protein Encoded by Region E3 of Adenovirus Is Expressed Early but is Greatly Amplified at Late Stages of Infection, Journal of Virology, (1992), Vol. 66, No. 6, pp. 3633-3642, American Society of Microbiology.		
	DD	TOLLEFSON et al., The Adenovirus Death Protein (E3-11.6K) Is Required at Very Late Stages of Infection for Efficient Cell Lysis and Release of Adenovirus from Infected Cells, Journal of Virology, (1996), Vol. 70, No. 4, pp. :2296-2306, American Society of Microbiology.		
	DE	TURCHI et al. Enzymatic completion of mammalian lagging-strand DNA replication, Prac. Natl. Acad. Sci. , (1994), Vol. 91, No. 21, pp. 9803-9807, Biochemistry.		
	DF	VIRTANEN et al., mRNAs from Human Adenovirus 2 Early Region 4, Journal of Virology, (1984), Vol. 51, pp. 822-831, American Society of Microbiology.		
	DG	WAGA et al., Reconstitution of Complete SV40 DNA Replication with Purified Replication Factors, Journal Biol. Chemistry, (1994), Vol. 269, No. 14, pp. 10923-10934, American Society for Biochemistry and Molecular Biology, Inc.		
	DH	WEINBERG et al., A Cell line that supports the growth of a defective early region 4 deletion mutant of human adenovirus type 2, Proc. Nat'l. Acad. Sci., (1983), Vol. 80, pp.:5383-5386, Genetics		
	DI	WOLD et al., E3 Transcription Unit of Adenovirus, Curr. Topics Microbiol. Immunology, (1995), Vol. 199, pp. 237-274.		
	DJ	WU et al., Processing of branched DNA intermediates by a complex of human FEN-a and PCNA, Nucleic Acid Research, (1996), Vol. 24, No. 11, pp. 2036-2043, Oxford University Press.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Docket No: 3802-165-27 NATL

**LIST OF RELATED CASES**

<b>Docket Number</b>	<b>Serial or Patent Number</b>	<b>Filing or Issue Date</b>	<b>Status</b>
3802-179-27	6852528	2/8/05	Granted
3802-206-27 CONT	0136707-A1	6/5/01	Published
3802-152-27 CONT	03-0026792	10/23/01	Published
3802-124-27 CIP	03-0039633	1/15/02	Published
3802-170-27	03-0104625	2/22/02	Published
N/A	5998205	12/7/99	Granted
N/A	6551587	4/22/03	Granted
3802-204-27	6432700	8/13/02	Granted
3802-125-27	6692736	2/17/04	Granted
3802-125-27	03-0148520	3/21/01	Published
3802-196-27	01-0053352	9/9/99	Published
3802-199-27	10/938227	9/9/04	Pending
3802-212-27	11/206,135	8/18/05	Pending
3802-137-27	5698443	12/16/97	Granted
3802-138-27 CIP	5871726	2/16/99	Granted
3802-139-27 CIP	6676935	1/13/04	Granted
3802-127-27	0068049-A1	12/6/00	Published
3802-144-27 CONT	04-0241857	4/13/04	Published
3802-143-27 CIP	03-0152553	5/2/02	Published
3802-131-27	5830686	11/3/98	Granted
3802-132-27 CIP	5648478	7/15/97	Granted
3802-133-27 CIP	6057299	5/2/00	Granted
3802-134-27 CONT	6136792	10/24/00	Granted
3802-197-27	6495130	12/17/02	Granted
3802-198-27 CONT	03-0118555	8/21/02	Published
3802-198-11 CONT2	11/153,458	6/16/05	Pending
3802-146-27	6254862	7/3/01	Granted
3802-147-27 NATL	09/509591	6/2/00	Pending
3802-149-27 CONT	6585968	7/1/03	Granted
N/A	6638762	10/28/03	Granted
3802-173-27 DIV	US-0009588	6/24/03	Published
3802-207-27	6197293	3/6/01	Granted
3802-208-27 CONT	6436394	8/20/02	Granted
3802-209-27 CONT	03-0091538	8/16/02	Published
3802-181-27	03-0068307	3/21/01	Published
3802-181-27CONT	11/166,234	6/27/05	Pending

The cases listed on this Notice of Related Cases include cases which may contain information that is material to patentability. The listing of a case on this Notice should not be taken as an indication or admission that any information contained therein is material. Prior art for each case listed on this Notice may have been cited. **The files corresponding to the listed cases, which are available to the Examiner, may not have not been examined to ascertain the materiality of any prior art therein.** Accordingly, the Examiner is requested to review the file for each case listed on this Notice in order to assess the materiality of such prior art.